Table A3.

Adverse events associated with each treatment (grade ≥ 3).

	LEN Combined with TIT (n = 30)	LEN Monotherapy (n = 85)	p-Value
HFSR	10.0% (3/30)	5.9% (5/80)	0.434
Hypertension	6.6% (2/30)	10.5% (9/85)	0.548
Urine protein	6.6% (2/30)	12.9% (11/85)	0.112
Fatigue	6.6% (2/30)	10.5% (9/85)	0.548
Diarrhea	6.6% (2/30)	4.7% (4/85)	0.657
Loss of appetite	3.3% (1/30)	10.5% (9/85)	0.200

Abbreviations: LEN, lenvatinib; TIT; Transcatheter intraarterial therapies; HFSR, hand-foot-skin-reaction.